NCT02741687 is a Phase 4 clinical trial of Sitagliptin in Hyperglycemia, sponsored by Emory University.

Who is sponsoring NCT02741687?

NCT02741687 is sponsored by Emory University.

What drugs are being tested in NCT02741687?

Interventions in NCT02741687: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine).

What condition does NCT02741687 study?

NCT02741687 studies Hyperglycemia.

Is NCT02741687 still recruiting?

NCT02741687 is currently completed. Last updated 30 May 2018.

Are results published for NCT02741687?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-05-30 · How we verify

NCT02741687

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Stress Hyperglycemia With the Use of DPP-4 Inhibitors in Non-diabetic Patients Undergoing Non-cardiac Surgery, a Pilot Study

Completed Phase 4 Results posted Last updated 30 May 2018

What this trial tests

Phase 4 trial testing Sitagliptin in Hyperglycemia in 80 participants. Completed in 1 April 2017.

Timeline

1 June 2016

Primary endpoint
1 April 2017

1 April 2017

Quick facts

Lead sponsor	Emory University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	80
Start date	1 June 2016
Primary completion	1 April 2017
Estimated completion	1 April 2017
Sites	2 locations across United States

Drugs / interventions tested

Sitagliptin (SITAGLIPTIN) — full drug profile →
Placebo
Supplemental insulin (insulin lispro) — full drug profile →
Supplemental insulin (insulin aspart) — full drug profile →
Long acting basal insulin (insulin detemir) — full drug profile →
Long acting basal insulin (insulin glargine) — full drug profile →

Conditions studied

Hyperglycemia — all drugs for Hyperglycemia →

Sponsor

Emory University

Who can join

Adults 18 to 80, any sex, with Hyperglycemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Number of Participants Experiencing Stress Hyperglycemia
Time frame: Up to time of discharge from hospital, an average of 10 days
The number of participants with at least one episode of stress hyperglycemia. Stress hyperglycemia is defined as a blood glucose \> 180 mg/dL.

Sponsor's own description

The purpose of this study is to compare sitagliptin with a placebo for the prevention of high glucose after general surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sitagliptin

Trials testing the same drug.

NCT07417618 — INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD) · active not recruiting
NCT07390110 — Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejectio · active not recruiting
NCT06851962 — Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes. · Phase 4 · active not recruiting
NCT06246799 — Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes · Phase 3 · recruiting
NCT06659718 — Emulation of the SOUL Diabetes Trial in Healthcare Claims · completed

Other recruiting trials for Hyperglycemia

Currently open trials in the same condition.

NCT06893341 — Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events · NA · recruiting
NCT06118931 — Time-restricted Eating, Window Timing, Type 2 Diabetes Status and Sex on Glycemic Control · NA · recruiting
NCT06184373 — Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot · recruiting
NCT07400549 — Prospective Exploratory Study on the Comprehensive Application Effectiveness of Exercise Prescription Decision Support T · NA · recruiting
NCT06694012 — Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2 · recruiting

Other Emory University trials

Trials by the same sponsor.

NCT06143345 — HIIT in Isolated IFG: A Proof-of-Concept Study · NA · withdrawn
NCT07189819 — Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait · NA · not yet recruiting
NCT06451055 — Low-calorie Diet in Isolated Impaired Fasting Glucose · NA · not yet recruiting
NCT07405476 — Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative I · Phase 2 · recruiting
NCT06708351 — Enhancing Cervical Cancer Screening and Treatment in Women Living With HIV in Kenya, the ENHANCE LINKAge Trial · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02741687 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Emory University
Last refreshed: 30 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02741687.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing